<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00256139</url>
  </required_header>
  <id_info>
    <org_study_id>24011</org_study_id>
    <nct_id>NCT00256139</nct_id>
  </id_info>
  <brief_title>CLEAR Study: Clinical Experience Acquired With Raptiva Study</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck KGaA</source>
  <brief_summary>
    <textblock>
      A multicentre, randomised, double blind, placebo controlled phase III study of subcutaneously
      administered Raptiva in the treatment of patients with moderate to severe psoriasis
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">October 2004</completion_date>
  <primary_completion_date type="Actual">October 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment type="Actual">793</enrollment>
  <condition>Moderate to Severe Psoriasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raptiva</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Plaque psoriasis covering ³10% of total BSA (see Appendix A)

          -  Diagnosis of psoriasis for at least 6 months

          -  A minimum PASI score of 12.0 at screening (see Appendix A)

          -  Patients who are either not controlled by, intolerant to or contraindicated to at
             least 2 currently available systemic therapies (e.g., photochemotherapy (PUVA),
             cyclosporin, corticosteroids, methotrexate, oral retinoids, MMF, thioguanine,
             hydroxyurea, sirolimus, azathioprine, 6 MP) (defined as &quot;high need&quot; patients)

          -  Body weight &lt;= £120 kg

          -  18 to 75 years old

          -  For women of childbearing potential, use of an acceptable method of contraception to
             prevent pregnancy and agreement to continue to practice an acceptable method of
             contraception for the duration of their participation in the study

          -  Willingness to hold sun exposure reasonably constant and to avoid use of tanning
             booths or other UV light sources during the study

          -  Willingness to enter Study

        Exclusion Criteria:

          -  Guttate, erythrodermic, or pustular psoriasis as sole or predominant form of psoriasis

          -  History of severe allergic or anaphylactic reactions to humanised monoclonal
             antibodies or fusion proteins that contain an Ig Fc region

          -  Clinically significant psoriasis flare during screening or at the time of enrollment

          -  History of or ongoing uncontrolled bacterial, viral, fungal, or atypical mycobacterial
             infection

          -  History of opportunistic infections (e.g., systemic fungal infections, parasites)

          -  Seropositivity for human immunodeficiency virus (HIV) Patients will undergo mandatory
             testing at screening. Patients who are positive for HIV will be excluded.

          -  Pregnancy or lactation

          -  WBC count &lt;4000/mL or &gt;14,000/mL

          -  Seropositivity for hepatitis B or C virus Patients will undergo testing during
             screening. Patients who are positive for hepatitis B antigen or hepatitis C antibody
             will be excluded.

          -  Hepatic enzymes ³3 times the upper limit of normal

          -  History of active tuberculosis (TB) or currently undergoing treatment for TB PPD
             testing or chest X-ray is required for high risk patients (see Appendix I). Patients
             with a positive PPD (not due to BCG vaccination) or chest X-ray will be excluded.

          -  Presence of malignancy within the past 5 years, including lymphoproliferative
             disorders Patients with a history of fully resolved basal cell or squamous cell skin
             cancer may be enrolled.

          -  Previous treatment with Raptiva (anti-CD11a)

          -  Diagnosis of hepatic cirrhosis, regardless of cause or severity

          -  Serum creatinine ³2 times the upper limit of normal

          -  Hospital admission for cardiac disease, stroke, or pulmonary disease within the last
             year

          -  History of substance abuse within the last 5 years

          -  Any medical condition that, in the judgment of the investigator, would jeopardize the
             patient's safety following exposure to study drug

        Note: Restrictions and/or directions apply to the following treatments during specified
        time periods prior to initial study drug administration and during the study:

          -  Systemic therapy for psoriasis (within 28 days prior to Study Day 0)

          -  Systemic immunosuppressive drugs for other indications (within 28 days prior to Study
             Day 0)

          -  Topical therapies for psoriasis (within 14 days prior to Study Day 0)

          -  Live or killed virus or bacteria vaccines (within 14 days prior to Study Day 0)

          -  Other vaccines or allergy desensitisation (it is recommended that these are scheduled
             at least 14 days prior to Day 0 or ³3 months after the last injection of study drug)

          -  Other experimental drugs or treatments (within 28 days or five half lives, whichever
             is longer, prior to Day 0) b Blockers, ACE inhibitors, interferons, quinidine,
             antimalarial drugs, or lithium (if clinically indicated, such medications are allowed
             but the dosage should be held constant from Day -28 throughout the study)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Patrick Natta, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Sponsor GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Serono International SA</name>
      <address>
        <city>Geneva</city>
        <zip>1202</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.biomedcentral.com/1471-5945/5/13</url>
    <description>CLEAR trial</description>
  </link>
  <results_reference>
    <citation>Dubertret L, Sterry W, Bos JD, Chimenti S, Shumack S, Larsen CG, Shear NH, Papp KA; CLEAR Multinational Study Group. CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Br J Dermatol. 2006 Jul;155(1):170-81.</citation>
    <PMID>16792770</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2005</study_first_submitted>
  <study_first_submitted_qc>November 18, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2005</study_first_posted>
  <last_update_submitted>January 13, 2017</last_update_submitted>
  <last_update_submitted_qc>January 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2017</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

